Essentials
In this crossover study the anticoagulant effects of rivaroxaban and apixaban were compared. Healthy volunteers received rivaroxaban 20 mg once daily or apixaban 5 mg twice daily. Rivaroxaban was associated with more prolonged inhibition of thrombin generation than apixaban. Rivaroxaban induced a clear prolongation of prothrombin time and activated partial thromboplastin time.
Summary. Background: The anticoagulant actions of the oral direct activated factor Xa inhibitors, rivaroxaban and apixaban, have not previously been directly compared. Objectives: To compare directly the steady-state pharmacokinetics and anticoagulant effects of rivaroxaban and apixaban at doses approved for stroke prevention in patients with non-valvular atrial fibrillation. Methods: Twenty-four healthy Caucasian male volunteers were included in this open-label, two-period crossover, phase 1 study (EudraCT number: 2015-002612-32). Volunteers were randomized to receive rivaroxaban 20 mg once daily or apixaban 5 mg twice daily for 7 days, followed by a washout period of at least 7 days before they received the other treatment. Plasma concentrations and anticoagulant effects were measured at steady state and after drug discontinuation. Results: Overall exposure was similar for both drugs: the geometric mean area under the plasma concentration-time curve for the 0-24-h interval was 1830 lg h L À1 for rivaroxaban and 1860 lg h L À1 for apixaban. Rivaroxaban was associated with greater inhibition of endogenous thrombin potential (geometric mean area under the curve relative to baseline during the 0-24-h interval: 15.5 h versus 17.5 h) and a more pronounced maximal prolongation relative to baseline of prothrombin time (PT) (1.66-fold versus 1.14-fold) and activated partial thromboplastin time (APTT) (1.43-fold versus 1.16-fold) at steady state than apixaban. Conclusions: Despite similar exposure to both drugs, rivaroxaban 20 mg once daily was associated with greater and more sustained inhibition of thrombin generation than apixaban 5 mg twice daily. Sensitive PT and APTT assays can be used to estimate the anticoagulant effects of rivaroxaban.
Introduction
Rivaroxaban and apixaban are direct oral anticoagulants (DOACs) that reversibly inhibit activated factor X (FXa). Unlike vitamin K antagonists (VKAs), such as warfarin, rivaroxaban and apixaban show predictable pharmacokinetic (PK) properties [1] . Thus, no routine coagulation monitoring is required to guide dosing [1] . Rivaroxaban (once daily) and apixaban (twice daily) are licensed for the prevention and treatment of various thromboembolic disorders, including: prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery; treatment of acute deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent DVT or PE; and prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) [2, 3] . Rivaroxaban twice daily, in combination with either acetylsalicylic acid (ASA) or ASA plus clopidogrel or ticlopidine, is approved in Europe for the prevention of atherothrombotic events after diagnosis of acute coronary syndrome with elevated cardiac biomarkers [2] . Rivaroxaban is also administered twice daily during the first 21 days of treatment for acute DVT or PE.
The differences between once-daily and twice-daily dosing regimens are potentially clinically relevant [4] . For example, in patients with NVAF who were taking edoxaban for the prevention of stroke and systemic embolism, twice-daily dosing regimens were associated with higher rates of bleeding than once-daily dosing regimens [5, 6] . These findings are specific to edoxaban, and do not necessarily apply to all drugs in the same class, but do serve to highlight the potential impact of a different dosing regimen on clinical outcomes. In addition, once-daily dosing has been associated with greater adherence to therapy than twice-daily dosing in the long-term treatment of cardiovascular disease [7] , which may improve clinical outcomes [8] .
It has been suggested that twice-daily versus once-daily dosing of DOACs affords greater continuity of action and is more forgiving of missed doses [9, 10] . Studies in healthy volunteers cannot answer questions on clinical efficacy, but may provide insights into pharmacologic action. A recent direct comparison of the pharmacokinetics and anti-FXa activity of rivaroxaban and apixaban at doses approved for the prevention of VTE (rivaroxaban, 10 mg once daily; apixaban, 2.5 mg twice daily) demonstrated that apixaban twice daily showed smaller peakto-trough fluctuations in plasma concentration and anti-FXa activity, as expected for a twice-daily versus once-daily regimen [10] . The authors of this study therefore suggested that twice-daily dosing is associated with less variability in exposure and greater continuity of drug action than once-daily dosing [10] . However, direct comparisons of the effects of rivaroxaban and apixaban on measures of anticoagulant activity, such as inhibition of thrombin generation, have yet to be carried out, and are required before conclusions can be drawn on the differences in continuity of action between the two drugs. In addition, global screening assays, such as prothrombin time (PT) and activated partial thromboplastin time (APTT), may be used to assess anticoagulant activity, and have been shown to be sensitive to rivaroxaban [11] [12] [13] [14] .
To our knowledge, this is the first study to compare directly the steady-state PK and pharmacodynamic (PD) properties (anti-FXa activity, thrombin generation, PT, and APTT) of rivaroxaban and apixaban when they are administered orally at the doses approved for prevention of stroke and systemic embolism in patients with NVAF.
For this indication, rivaroxaban is administered at a dose of 20 mg once daily [2] and apixaban at a dose of 5 mg twice daily [3] in patients without an indication for dose reduction. These doses of rivaroxaban and apixaban are also approved for the maintenance treatment of patients with acute DVT and PE, following an initial intensified treatment phase (rivaroxaban, 15 mg twice daily for the first 3 weeks; apixaban, 10 mg twice daily for the first 7 days) [2, 3] .
The primary objective of this study was to compare the PK properties of rivaroxaban 20 mg once daily and apixaban 5 mg twice daily on day 7 at steady state (when the rate of intake is in dynamic equilibrium with the rate of elimination [15] [16] [17] ) and after drug discontinuation. Secondary objectives were to examine corresponding surrogate measures of the effectiveness of the drugs, namely anti-FXa activity, thrombin generation, PT, and APTT, and to explore their relationships with the plasma concentrations of both drugs. These data will help to further inform physician decisions regarding DOACs and the appropriate dosing regimen.
Methods

Volunteers
Healthy Caucasian male volunteers aged 18-55 years with a body mass index of 18.0-29.9 kg m À2 at screening were eligible for inclusion. Key exclusion criteria were known coagulation disorders or conditions that increase bleeding risk (e.g. peptic ulcer), susceptibility to common types of bleeding (e.g. nasal bleeding), evidence of thyroid disorders, creatinine clearance of < 90 mL min À1 , use of medications that may impact on the study objectives, relevant diseases or treatments within 4 weeks of starting study drug, and a history of heavy smoking or drug or alcohol abuse. All volunteers provided written informed consent before taking part in any procedures related to the study. Study documentation was reviewed and approved by the Ethics Committee of the North Rhine Medical Council (D€ usseldorf, Germany). The study (EudraCT number: 2015-002612-32) was conducted in accordance with the ethical principles of the Declaration of Helsinki (1964, last revised version) and in compliance with the International Conference on Harmonization guidelines for Good Clinical Practice and German drug law.
Study design
This study was a randomized, open-label, two-period, two-treatment crossover study (Fig. 1) . Screening was carried out within the 14-day period preceding the first administration of a study drug. Eligible volunteers were randomized by an independent group, which used a computer program to generate the allocation sequence to randomize volunteers to receive either rivaroxaban 20 mg once daily (at 08:00 h with a standardized breakfast) or apixaban 5 mg twice daily (at 08:00 h and 20:00 h with a standardized breakfast and standardized dinner, respectively) for 7 days. Volunteers took study medication (marketed immediate-release tablets) in the sitting or standing position with 240 mL of still water under the supervision of the investigator. Blinding was not carried out, because the PK and PD parameters being studied were not expected to be influenced by knowledge of treatment allocation.
During each treatment period, rivaroxaban and apixaban were administered on days 1-7. Volunteers were admitted to the study site (CRS Clinical Research Services M€ onchengladbach, M€ onchengladbach, Germany) 1 day before the first administration of each study drug, and discharged on day 10, with continuous observation and monitoring for adverse events (AEs) until discharge. The first 7-day treatment period was followed by a washout period of at least 7 days before volunteers received the other drug. All volunteers attended a follow-up visit within 7 days of the final administration of the second study drug.
PK assessments
Blood samples for PK analysis were collected in lithium heparinate tubes. For rivaroxaban, samples were taken before tablet intake on days 1 and 7 of the treatment period, and at 0. For each dosing interval (0-24 h for rivaroxaban, and 0-12 h and 12-24 h for apixaban), the maximum observed plasma concentration (C max ), minimum observed plasma concentration (greater than the LLOQ) (C min ), time to maximum plasma concentration (t max ) and observed plasma concentration at the end of the dosing interval were determined. Calculated parameters included: area under the curve (AUC) of plasma concentrationtime data for each dosing interval (AUCs) and for the time period 0-24 h (AUC 0-24 ); ratio of maximum to minimum observed plasma concentrations (C max /C min ); peakto-trough fluctuation over one dosing interval at steady state; total body clearance after oral administration; and average steady-state plasma concentration after multiple dosing (C av,md ). Elimination half-life and apparent volume of distribution at steady state after oral administration were determined after the final dose of each drug. PK parameters were calculated with the model- independent (compartment-free) method and WINNONLIN software (version 6.2.1; Pharsight Corporation, Mountain View, CA, USA) in conjunction with STATISTICAL ANALYSIS SYSTEM software, version 9.3.
PD assessments
Blood samples for the analysis of steady-state PD parameters of rivaroxaban were taken before dosing on days 1 and 7 of the treatment period, and then at 1, 2, 3, 4, 6, 12, 18, 24, 36, 48 and 60 h after dosing on day 7. For apixaban, samples were taken before dosing on days 1 and 7, and again on day 7 at 1, 2, 3, 4, 6, 8 and 12 h after the morning dose, and at 1, 2, 3, 4, 6, 12, 18, 24, 36, 48 and 60 h after the evening dose. For anti-FXa activity, PT and APTT assays, blood was collected into tubes containing sodium citrate (3.2%; 1 : 10), and centrifuged for 15 min at 2500 9 g and 15°C, and plasma was aliquoted into fresh tubes and flash-frozen at À 70°C. For thrombin generation assays, plasma aliquots from the first centrifugation were centrifuged again under identical conditions and flash-frozen at À 70°C.
Anti-FXa activity was determined with a validated method by use of the STA-Liquid Anti-Xa assay and STA-rivaroxaban and STA-apixaban calibrators and controls (Diagnostica Stago, Asni eres sur Seine, France) on an ACL TOP 550 CTS platform (Instrumentation Laboratory, Bedford, MA, USA). Plasma was added to a reagent mix containing exogenously added FXa and a chromogenic FXa-specific substrate. Signal generation was assessed photometrically, and was influenced by the concentration of FXa inhibitors in the plasma, which reduce enzymatic conversion of the chromogenic substrate. The anti-FXa activity of each drug in terms of micrograms of inhibitor per liter of plasma (lg L À1 ) was determined from rivaroxaban and apixaban calibration curves.
PT and APTT assays were performed with the Stago STA compact coagulation analyzer (Stago Deutschland, D€ usseldorf, Germany) and the reagents STA Neoplastine CI Plus 10 (PT assay) and STA C.K. Prest 5 (APTT assay) (Stago Deutschland). The reportable range for both tests was 10-180 s. The thrombin generation assay (calibrated automated thrombogram; all reagents from Diagnostica Stago) was conducted with a validated method [18] in which thrombin generation was triggered in double-centrifuged, citrated plasma with tissue factor (final concentration, 5 pM) and phospholipids (4 lM). Thrombin activity resulted in conversion of a fluorogenic substrate that was measured continuously for 90 min with an MTP fluorometer (Diagnostica Stago), which relates fluorescence to a thrombin calibrator. Thrombin generation assay parameters (endogenous thrombin potential [ETP], peak, time to peak, and lag time) were derived with Thrombinoscope software (Thrombinoscope, Maastricht, The Netherlands).
For each PD parameter, maximum effect (E max ) and AUC for different time intervals were calculated so that comparisons could be made between morning and evening doses of apixaban and between the two drugs over the 24-h dosing interval. AUC 0-12 represents the time period 0-12 h after the last dose of rivaroxaban and the morning dose of apixaban, AUC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] represents the time periods 12-24 h after the last dose of rivaroxaban and 0-12 h after the evening dose of apixaban and AUC 0-24 represents the 24-h time period after the last dose of rivaroxaban and the morning dose of apixaban. Relative changes from baseline were investigated for all PD parameters, except anti-FXa activity, for which absolute values were evaluated.
Safety assessments
The following safety assessments were performed in the morning (before dosing) on days 1, 4, 6 and 7 of each treatment period and at the follow-up visit: measurement of vital signs, hematologic analysis, urinalysis, and 12-lead electrocardiogram (ECG). Concomitant medication and AEs were monitored throughout the study, with AEs being classified according to intensity (mild, moderate, or severe) and importance (serious or non-serious).
Statistical methods
On the basis of findings in previous phase 1 studies [19] , the sample size of 24 healthy volunteers was expected to provide appropriate precision. Selected PK and PD characteristics of rivaroxaban and apixaban were analyzed in an explorative manner on the assumption of log-normally distributed data. To compare the key PK and PD parameters of rivaroxaban and apixaban, an ANOVA that included sequence, subject (sequence), period and treatment effects was applied.
On the basis of these analyses, point estimates and exploratory 90% confidence intervals for the treatment or dosing interval ratios were calculated by retransformation of the logarithmic results given by the ANOVA. Exploratory analyses were performed to compare PK variables for the morning and evening doses of apixaban by the use of paired t-tests. Data are presented as geometric mean and standard deviation, unless stated otherwise. P < 0.05 was considered to denote statistical significance. Correlation plots were used to visualize the relationship between plasma concentration and anti-FXa activity for each drug.
Results
Demographics and disposition
The first volunteer entered the study on 3 September 2015, and the last volunteer completed the study on 21 October 2015. In total, 24 healthy Caucasian male volunteers received study drugs (Table 1 ). All 24 volunteers completed the study (Fig. 1) .
Pharmacokinetics
Overall exposure (AUC 0-24 of plasma concentration-time data) and C av,md on day 7 were similar for both drugs (Table 2) . Rivaroxaban (once daily) showed significantly higher C max and lower C min values than apixaban (twice daily); thus, C max /C min was significantly higher for rivaroxaban than for apixaban ( Fig. 2; Table 2 ). The morning dose of apixaban was associated with a higher C max and a higher C max /C min ratio than the evening dose (Table 2 ). Individual t max was reached at an earlier time point following the morning dose than following the evening dose of apixaban; however, geometric mean values for the latter were similar ( Table 2 ). The coefficients of variation of AUC 0-24 of plasma concentration-time data were similar for rivaroxaban and apixaban (19.5% and 21.6%, respectively). The coefficients of variation of C max and C min were also similar for rivaroxaban (18.2% and 44.3%, respectively) and the morning (19.1% and 34.0%, respectively) and evening (21.5% and 38.8%, respectively) doses of apixaban (Table 2) .
Pharmacodynamics
Anti-FXa activity The time-course profiles of anti-FXa activity for rivaroxaban and apixaban mirrored their plasma concentration-time profiles. Rivaroxaban was associated with significantly greater E max and AUC 0-12 and significantly lower AUC 12-24 than apixaban; AUC 0-24 was significantly greater for rivaroxaban than for apixaban (Table S1 ). There was a close relationship between the plasma concentration and anti-FXa activity of each drug (Fig. S1 ).
Thrombin generation
The overall inhibitory effect of rivaroxaban on ETP for the 24-h dosing interval relative to baseline was significantly greater than that of apixaban AUC 0-24 , area under the plasma concentration-time curve for the time period 0-24 h; AUC s , area under the plasma concentration-time curve for the actual dosing interval; C av,md , average steady-state plasma concentration after multiple dosing; CL/F, total body clearance after oral administration; C max , maximum observed plasma concentration; C min , minimum observed plasma concentration (greater than the lower limit of quantification); C trough , plasma concentration at the end of the dosing interval; PTF, peak-to-trough fluctuation over one dosing interval at steady state; t 1/2 , elimination half-life; t max , time to reach maximum plasma concentration; V ss /F, apparent volume of distribution at steady state after oral administration. Data are presented as geometric mean (% coefficient of variation) unless stated otherwise. *Comparison of rivaroxaban with the evening dose of apixaban. †Comparisons of morning and evening doses of apixaban made with a paired t-test. ‡Median (range).
(AUC 0-24 , 15.5 h for rivaroxaban and 17.5 h for apixaban; Fig. 3A ; Table S1 ). During the time period 0-12 h after the last dose of rivaroxaban and the morning dose of apixaban, the inhibitory effects of rivaroxaban on ETP relative to baseline were significantly greater than those of apixaban (AUC 0-12 , 6.36 h for rivaroxaban and 8.69 h for apixaban; Table S1 ). In the time period 12-24 h after the last dose of rivaroxaban and 0-12 h after the last (evening) dose of apixaban (AUC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ), the effects of rivaroxaban and apixaban on inhibition of ETP were similar (Table S1 ). Rivaroxaban also showed significantly greater suppression of the peak of thrombin generation during the 0-24-h dosing interval (AUC 0-24 , 6.59 h for rivaroxaban and 7.84 h for apixaban; Fig. 3B ; Table S1 ). Furthermore, the effects of rivaroxaban on prolongation of thrombin generation lag time and prolongation of the time to the peak of thrombin generation were significantly greater than those of apixaban for all measured parameters (E max , AUC 0-12 , AUC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , and AUC 0-24 ; Figs 4 and 5; Table S1 ). At time points 36 h and 48 h after the last dose of rivaroxaban (equivalent to 24 h and 36 h after the last dose of apixaban), the inhibitory effects of rivaroxaban on the peak and time to peak of thrombin generation were significantly greater than those of apixaban (Table S2) . Timecourse analysis of the inhibition of ETP over the period 24-60 h after intake of the last dose of each drug demonstrated numerically greater inhibition of ETP with rivaroxaban than with apixaban (Fig. 3) ; however, this difference did not reach statistical significance.
Some volunteers showed smaller prolongations of thrombin generation lag time (Fig. 4) in response to apixaban than might be expected on the basis of plasma drug concentrations. Individual plasma concentrations and thrombin generation lag time data from eight volunteers whose thrombin generation lag time responses to apixaban were among the lowest of all volunteers are shown together with the corresponding rivaroxaban data in Fig. S2 . The distribution of plasma concentrations of apixaban and rivaroxaban in these individuals was similar to the overall distribution of all volunteers. However, the effects of apixaban but not of rivaroxaban on thrombin generation lag time and time to peak were smaller than might be expected on the basis of plasma concentrations ( Figs S2 and S3 ).
PT and APTT Rivaroxaban was associated with significantly greater maximal prolongation of the global coagulation parameters PT and APTT than apixaban (Table S1 ). The time-course profiles of the effects of rivaroxaban on PT and APTT (Fig. 6 ) mirrored its plasma concentration-time profile (Fig. 2) . At steady state on day 7, rivaroxaban was associated with a 1.66-fold prolongation of PT and a 1.43-fold prolongation of APTT at E max (Table S1 ). The corresponding effects of apixaban on PT and APTT were less pronounced (Fig. 6) , and did not closely mirror the apixaban plasma concentration-time profile (Fig. 2) ; at steady state on day 7, apixaban was associated with a 1.14-fold prolongation of PT and a 1.16-fold prolongation of APTT at E max (Table S1 ).
Safety
Rivaroxaban and apixaban were well tolerated. In total, six volunteers experienced treatment-emergent AEs; however, none of these were judged to be related to the study drugs, and all were mild to moderate and resolved without treatment. No deaths or serious AEs were reported, and no volunteers discontinued treatment. There were no findings of clinical relevance with respect to laboratory tests, vital signs, ECGs, or physical examinations.
Discussion
To our knowledge, this is the first study in which a direct comparison has been made between the effects of rivaroxaban 20 mg once daily and apixaban 5 mg twice daily on thrombin generation, global coagulation assays (PT and APTT) and anti-FXa activity in healthy volunteers. In the context of this study, we observed that, at steady state, once-daily dosing of rivaroxaban 20 mg is associated with significantly greater inhibition of thrombin generation than twice-daily dosing of apixaban 5 mg during the 24-h dosing interval. The PK results from this study are generally consistent with previously published data for rivaroxaban and apixaban [10, 17, 20, 21] . The overall exposures to rivaroxaban and apixaban over the 24-h period (area under the plasma concentration-time curve from time 0-24 h) on day 7 were similar. C max was higher and C min was lower for rivaroxaban than for apixaban, as expected for oncedaily versus twice-daily dosing. The finding that the morning dose of apixaban was associated with higher C max and a higher C max /C min ratio than the evening dose may be explained by circadian variations in gastrointestinal function, hepatic and intestinal enzyme activity, and organ blood flow, which can influence drug absorption and elimination [22] [23] [24] . In agreement with previous studies, the anti-FXa activities of both drugs mirrored their plasma concentration-time profiles [10, 17, 20, 21] .
Overall, the inhibitory effects of rivaroxaban on thrombin generation in this study were significantly greater than those of apixaban in the 0-24-h dosing interval, as determined by calculation of AUC for each parameter related to thrombin generation. Furthermore, rivaroxaban showed significantly greater inhibitory effects than apixaban on thrombin generation peak and time to peak of thrombin generation at 36 h and 48 h after the last dose (equivalent to 24 h and 36 h after the last [evening] dose of apixaban). These data underscore the recommendation that rivaroxaban should be discontinued at least 24 h before invasive procedures and surgical interventions [2] . In several volunteers, the effects of apixaban on thrombin generation lag time and time to peak of thrombin generation were found to be lower than expected on the basis of plasma concentrations. However, these volunteers showed responses to rivaroxaban that were within the expected range. Taken together, these data suggest that it is not necessarily appropriate to think of the twice-daily dosing regimen of apixaban as more forgiving of missed doses than the once-daily dosing regimen of rivaroxaban, as has been proposed [9] , and provide further valuable evidence regarding DOACs and the potential differences between dosing regimens.
A key advantage of DOACs over VKAs is that routine coagulation monitoring is not required to guide dosing. However, in some clinical situations (such as medical emergencies that require prompt decision-making), it may still be beneficial to assess the extent of drug exposure and how this relates to anticoagulant effect [25] . The present data demonstrate the close relationship between the plasma concentration-time profiles (determined by LC-MS/MS) and the anti-FXa activities of rivaroxaban and apixaban, and therefore support the use of chromogenic anti-FXa assays to estimate plasma concentrations. However, anti-FXa assays are not routinely available in the clinical setting and, at present, there is no consensus on their use for assessing DOAC activity [26] . The finding that rivaroxaban, but not apixaban, caused a clear prolongation of PT and APTT is in agreement with other recently published data [13] , although it is acknowledged that the extent of prolongation of coagulation assessed with these assays depends on the reagents used [27, 28] . Nevertheless, a recent clinical guideline recommends the use of PT tests to determine whether clinically relevant plasma concentrations of rivaroxaban may be present during an occurrence of bleeding; this strategy is not recommended for patients receiving apixaban [29] . The limitations of this study include those inherent to phase 1 PK/PD studies in which surrogate markers of a drug's effectiveness (i.e. pharmacologic properties) are assessed, and the observed dissociation between PK and PD parameters must be interpreted within the context of our study objectives, study design, and the parameters analysed. Thus, it is unclear whether the observed dissociation applies to PD parameters that were not investigated (e.g. D-dimer), or, more importantly, to clinical outcomes, including thromboembolic or bleeding events. Therefore, caution is warranted when the clinical implications of the findings are interpreted.
In conclusion, once-daily dosing of rivaroxaban 20 mg and twice-daily dosing of apixaban 5 mg result in similar overall plasma concentrations and exposures over a 24-h interval. Thus, these data support the once-daily dosing regimen of rivaroxaban and confirm the need for twicedaily dosing of apixaban. Despite the similar exposures, rivaroxaban treatment is associated with greater and more sustained inhibition of thrombin generation than apixaban. These data are therefore not in agreement with previously reported suggestions that twice-daily dosing of apixaban leads to more consistent anticoagulation than once-daily dosing of rivaroxaban [10] , or that superior therapeutic coverage is achieved with twice-daily dosing regimens [9] . The present findings do, however, confirm previous reports suggesting that the anticoagulant activity of rivaroxaban may be more readily assessed than that of apixaban in the clinical setting, provided that sensitive PT or APTT assays are used.
Addendum
K. Thelen participated in generating, evaluating and presenting PK data. D. Kubitza, S. Heitmeier, and S. Schwers were involved in generating, evaluating and presenting PD data. M. Becka performed statistical analyses. R. Kreutz, P. B. Persson, and M. Hemmrich participated in data evaluation and presentation. All authors contributed to the study concept, design, and implementation, were involved in revising the manuscript for important intellectual content, and approved the final version of the manuscript. Fig. S1 . Correlation plot showing the relationship between plasma concentration and anti-factor Xa activity of rivaroxaban and apixaban. Fig. S2 . Plasma concentrations and effects of rivaroxaban and apixaban on thrombin generation lag time in selected individual volunteers. Fig. S3 . Effects of rivaroxaban and apixaban on time to the peak of thrombin generation. Table S1 . E max and AUC of pharmacodynamic parameters for rivaroxaban 20 mg once daily and apixaban 5 mg twice daily on day 7. Table S2 . Pharmacodynamic parameters at time points after dosing of rivaroxaban 20 mg once daily and apixaban 5 mg twice daily on day 7.
